United States securities and exchange commission logo





                               June 3, 2021

       Shalabh Gupta, M.D.
       Chief Executive Officer, President and Chairman
       Unicycive Therapeutics, Inc.
       5150 El Camino Real, Suite A-32
       Los Altos, CA 94022

                                                        Re: Unicycive
Therapeutics, Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed May 21, 2021
                                                            File No. 333-256367

       Dear Dr. Gupta:

              We have reviewed your registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-1 filed May 21, 2021

       Exclusive Forum, page 86

   1.                                                   We note that the choice
of forum provision in your restated certificate to be effective upon
                                                        the completion of the
offering identifies the Court of Chancery of the State of Delaware as
                                                        the exclusive forum for
certain litigation, including any "derivative action." We further
                                                        note your disclosure on
pages 33 and 86 of your prospectus stating that the such provision
                                                        will not apply to suits
brought to enforce a duty or liability created by the Securities Act or
                                                        the Exchange Act.
Please either (i) amend the provision in your restated certificate to
                                                        clearly state that the
provision does not apply to federal securities law claims or applies
                                                        only to state law
claims, as applicable, or (ii) provide reasonable assurance that you will
                                                        make future investors
aware of the provision   s limited applicability, for example by
                                                        including such
disclosure in your future Exchange Act reports.
 Shalabh Gupta, M.D.
Unicycive Therapeutics, Inc.
June 3, 2021
Page 2

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact Ibolya Ignat at 202-551-3636 or Brian Cascio at
202-551-3676 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jeffrey Gabor at 202-551-2544 or Celeste Murphy at 202-551-3257 with
any other
questions.



                                                           Sincerely,
FirstName LastNameShalabh Gupta, M.D.
                                                           Division of
Corporation Finance
Comapany NameUnicycive Therapeutics, Inc.
                                                           Office of Life
Sciences
June 3, 2021 Page 2
cc:       Jeffrey Fessler, Esq.
FirstName LastName